Clinical trials: Proton Pump Inhibitors
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Dysbiosis, Gastroesophageal Reflux Disease (GERD)
Effect of Bioflor on Gut Microbiota in Proton-Pump Inhibitor Users
Proton-pump inhibitors (PPIs) are widely used to treat acid-related stomach problems, such as heartburn and acid reflux. Long-term use of PPIs has been linked to changes in the gut bacteria and fungi (called the gut microbiota)…
- Trial name
- NCT07852676
- Testing
- Saccharomyces Boulardii 250 MG, Proton Pump Inhibitors (PPI)
- Where
- 3 sites in South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Gastroesophageal Reflux Disease
Esomeprazole in PPI Failures - IMPROVE
The purpose of this study is to assess how PPI treated GERD patients with insufficient symptom control will benefit from a change in management by providing a more efficient acid secretion inhibition during 4 weeks, by evaluation…
- Trial name
- NCT00272701
- Testing
- Esomeprazole, Other PPI marketed in Sweden
- Where
- 42 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Breast Cancer, Metastasis, Neoplasm
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer
The objectives of this study are to evaluate the efficacy and tolerability of high dose proton pump inhibitor combined with chemotherapy in metastatic breast cancer.
- Trial name
- NCT01069081
- Testing
- Arm C, Arm B, Arm A
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Gastroesophageal Reflux, Small Intestinal Bacterial Overgrowth
Intestinal Adsorbent and Breath Gas Levels
To determine the effect of an intestinal adsorbent on hydrogen and methane breath levels in patients who have been on long term PPI therapy reporting reflux and abdominal symptoms at baseline.
- Trial name
- NCT04492839
- Testing
- Intestinal adsorbent
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Dr Anthony Hobson
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
Helicobacter pylori (H. pylori) gastritis is a common bacterial infection among the elderly population. H. pylori infection causes chronic progressive gastric inflammation, peptic ulcer disease and gastric cancer.
- Trial name
- TRIVON (NCT03908619)
- Testing
- Omeprazole 20mg, Esomeprazole 20mg, Rabeprazole Sodium 20mg
- Where
- Singapore
- Volunteers
- 252 people
- Sponsor
- Changi General Hospital
Peptic Ulcer Hemorrhage
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding.
- Trial name
- NCT03362281
- Testing
- Ilaprazole, Omeprazole, Ilaprazole tablet
- Volunteers
- 540 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.
- Trial name
- NCT06417229
- Testing
- BMS-986365, Rabeprazole
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Celgene
Peptic Ulcer Hemorrhage, Peptic Ulcer, Acute With Hemorrhage
Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding
We prepare this study to compare the efficacy of intermittent intravenous PPI infusion (relatively low dose PPI therapy) than continous PPI infusion method.
- Conditions
- Peptic Ulcer Hemorrhage, Peptic Ulcer, Acute With Hemorrhage, Peptic Ulcer, Proton Pump Inhibitor Overdose
- Trial name
- NCT03814421
- Testing
- intermittent (40mg as a bolus injection daily for 72hours)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Changwon Hospital
Hepatitis C, Swallowing Disorder
Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.
Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor…
- Trial name
- COPA (NCT03513393)
- Testing
- velpatasvir
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy Volunteers
Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults
The purpose of this study is to evaluate the effects of a common over-the-counter medication, omeprazole, on the normal gut bacteria and inflammation in the body in healthy older adults.
- Trial name
- NCT02844621
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-erosive Gatroesophageal Reflux Disease
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease
For ERD(erosive reflux disease), which pathogenesis is mainly the acid reflux mechanism, primary treatment is therefore PPI. However, NERD(non-erosive reflux disease) is much more complex than ERD and there are more factors…
- Trial name
- NCT03436914
- Testing
- PPI
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Yonsei University
Gastrointestinal Disease
Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population
This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.
- Trial name
- ECHO (NCT03118778)
- Where
- China
- Volunteers
- 90,895 people
- Sponsor
- AstraZeneca
Peptic Ulcer
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
The purpose of this study is to compare the gastric acid suppression profile among different regimen (Oral Vs Intravenous)of administration of proton pump inhibitor - Esomeprazole by 24hours intragastric pH monitoring.
- Trial name
- NPH (NCT00471029)
- Testing
- esomeprazole
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Pamela Youde Nethersole Eastern Hospital
Healthy
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV).
- Trial name
- NCT04984525
- Testing
- SYNB1934, SYNB1618
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Synlogic
Gastroesophageal Reflux Disease (GERD)
Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone
Many patients with acid reflux disease do not improve with regular doses of proton pump inhibitors (e.g., omeprazole). The goals of this clinical trial is the to see if taking MARIAL®, in combination with omeprazole, for one…
- Trial name
- GENYAL® (NCT04130659)
- Testing
- MARIAL® + PPI (generic Omeprazole), PPI alone (generic omeprazole), MARIAL® alone
- Where
- 5 sites in Italy, Romania
- Volunteers
- 110 people
- Sponsor
- Nekkar Lab Srl
Heartburn, Gastroesophageal Reflux Disease
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn
The purpose of this research study is to determine in heartburn patients with nonerosive disease if detecting the presence of a fragment of the protein e-cadherin in esophageal epithelium or the amount of fragments of e-cadherin…
- Trial name
- NCT01149395
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of North Carolina, Chapel Hill
Helicobatcer Pylori, First-Line Eradication
Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection
Most international treatment guidelines currently recommend a 14-day bismuth quadruple therapy as the first-line treatment for Helicobacter pylori infection, especially in areas with high clarithromycin resistance.
- Trial name
- NCT07788053
- Testing
- Bismuth, Bismuth quadruple therapy
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chih-An Shih, MD